drugset / Trial / NCT04829383
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Phase 2
Completed
6 enrolled
Howard S Hochster
Genentech, Inc. · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelTreatment
Summary
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Timeline
- Start
- 2021-03-22
- Primary completion
- 2024-06-19
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |